CBCE The Center for Biomedical Continuing Education
Upcoming Activities



Seventh Annual Recent Advances and New Directions in Cancer Therapy Conference, In Partnership with the California Cancer Consortium
San Francisco, California
 March 28 - 30, 2008
Description
Faculty
Agenda
Location
 
Statement of Need
 Our understanding of cancer initiation, progression, and response to treatment has significantly advanced in the past decade. This understanding, coupled with technical achievements in radiation, bioinformatics, and genome/proteome analysis, has expanded oncologists' diagnostic abilities and treatment options. These rapid advances also underscore the need to integrate the latest clinical findings into widespread practice. Targeted therapeutics, which rely on the molecular characteristics of disease, offer hope for improving patient outcomes on a more individual basis. Current molecular targets range from cell-surface receptors, such as the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF); mediators of intracellular signaling, such as Raf kinase, mammalian target of rapamycin, and heat-shock proteins; and regulators of cellular processes, such as the cell cycle and cellular motility, to antiapoptotic factors and angiogenic agents. In addition, several novel therapeutic approaches are being studied, including the use of epigenetic agents to reactivate silenced genes, as well as the use of antisense molecules to silence inappropriately active genes. These treatment advances can be used in single-agent regimens or incorporated into combination therapies. The Seventh Annual Recent Advances and New Directions in Cancer Therapy Conference, in Partnership With the California Cancer Consortium, will provide participants with updates on cutting-edge therapeutic strategies for a variety of tumor types, including lung, breast, gastrointestinal, and genitourinary cancers.

Target Audience

This program is intended for medical oncologists, radiation oncologists, surgical oncologists, community practitioners, nurses, pharmacists, advanced practitioners, nurse practitioners, physician assistants, and other health care professionals interested in the care and treatment of patients with cancer.



Educational Objectives

After participating in this educational activity, attendees should be able to:
1. Evaluate the safety and efficacy of current and novel targeted agents in the treatment of patients with cancer based on the results of recent clinical trials.
2. Describe clinical trial data supporting the safety and efficacy of combining targeted agents with other treatment modalities in the treatment of patients with cancer.
3. Evaluate the safety and efficacy of therapeutic agents that target angiogenesis in cancer.
4. Compare the safety and efficacy of agents that target components of cellular signal transduction pathways in the treatment of patients with cancer.
5. Analyze the predictive and prognostic value of molecular and clinical biomarkers for the management of patients with cancer.
6. Describe advances in epigenetic approaches for the treatment of patients with cancer.
7. Describe the rationale for and assess recent developments in targeting cancer stem cells.
8. Discuss the impact of genomics, proteomics, and metabolomics on drug development and in personalizing treatment approaches for patients with cancer.



Method of Participation
 Lectures, visual aids, presentations, and panel/round table discussions will be utilized to engage attendees and enhance the learning process. All attendees will receive a comprehensive CD-ROM of the program presentations approximately 4-6 weeks after the conference.

Accreditation

Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the Essential Areas and policies of the ACCME.

The CBCE designates this educational activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.

Nurses: The CBCE™ (The Center for Biomedical Continuing Education) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The CBCE designates this educational activity for 13.5 contact hour(s). Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Pharmacists: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
CPE Credit: 13.5 contact hours or 1.350 CEUs
Universal Program Number: 195-000-08-003-L01-P



Certificate
 The Evaluation and Request for Credit Form must be completed and returned to the CBCE following this activity to obtain credit. Participants will receive their certificate 4-6 weeks after the CBCE receives their form.

Acknowledgment

The CBCE gratefully acknowledges the educational grants provided by:

Eli Lilly and Company
Genentech BioOncology

Abraxis BioScience, Inc.
AstraZeneca Pharmaceuticals LP
Pfizer Inc.

Abbott Laboratories
Bayer HealthCare Pharmaceuticals, Inc./Onyx Pharmaceuticals, Inc.
ImClone Systems Incorporated
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Ortho Biotech Products, LP
sanofi-aventis



Registration Fee

The registration fee covers participation at all conference sessions, meeting materials, and food functions per the agenda.
• Physician, nurse, and pharmacist early-bird registration (in practice or academic research, registrations must be received and paid in full by Friday, February 15, 2008): $50
• Physician (in practice or academic research): $150
• Nurse, pharmacist, and other health care professionals (in practice or academic research): $75
• Fellow (in practice or academic research): Complimentary
• Industry/All others: $2,495 (This category is defined by the CBCE as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.)




Conference Cancellation Policy
 If a cancellation notice is received in writing by Friday, March 7, 2008, 75% of the registration fee will be refunded. All cancellation requests should be sent to the CBCE at the address below.

American Disability Act
 The CBCE fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of support services, please notify the CBCE staff prior to the program to request services.

Disclaimer
 The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or the commercial supporters. This material has been prepared based on a review of multiple sources of information, but is not exhaustive of the subject matter. Participants are advised to critically appraise the information presented, and are encouraged to consult the available literature on any product or device mentioned in this program.




© 2010 The CBCE™. All rights reserved.